Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190246 | 1.00 | APP (0.59) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL8371513 | 0.91 | ALDH1A1 (0.59) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL1982944 | 0.89 | ALDH1A1 (0.58) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL9908262 | 0.89 | ALDH1A1 (0.58) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL10032066 | 0.87 | ALDH1A1 (0.49) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL4595052 | 0.86 | APP (0.53) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL3861084 | 0.86 | APP (0.53) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2229143 | 0.86 | APP (0.53) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL10298225 | 0.86 | ALDH1A1 (0.51) | APPALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL851166 | 0.84 | ALDH1A1 (0.66) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393810-A1 | DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF | HTA Co., Ltd. (CN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020140924-A1 | DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO AΒ PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF | 原子高科股份有限公司 | 2020-07-09 | — | — | WO | disclosed |
| CN-109704988-B | Dihydrazone compound with high affinity with A β protein and Tau protein, derivative and application thereof | 北京师范大学 | 2020-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393810-A1 | DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF | MAPT, APP, PSEN1 | APP 2/4885ALDH1A1 1343/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.